Torii Pharmaceutical Co., Ltd. (4551.T)
JPY 4300.0
(0.82%)
JPY 4300.0
(0.82%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 5.27 Billion JPY | -12.92% |
| 2022 | 5.97 Billion JPY | 13.82% |
| 2021 | 5.04 Billion JPY | -4.92% |
| 2020 | 4.68 Billion JPY | 109.01% |
| 2019 | 38.5 Billion JPY | -56.26% |
| 2018 | 3.87 Billion JPY | -19.26% |
| 2017 | 7.45 Billion JPY | 41.94% |
| 2016 | 5.23 Billion JPY | -19.01% |
| 2015 | 6.37 Billion JPY | 30.1% |
| 2014 | 5.06 Billion JPY | -18.46% |
| 2013 | 7.06 Billion JPY | 54.86% |
| 2012 | 3.85 Billion JPY | -27.49% |
| 2011 | 6.24 Billion JPY | -26.16% |
| 2010 | 3.89 Billion JPY | -36.39% |
| 2009 | 8.4 Billion JPY | 12.99% |
| 2008 | 7.45 Billion JPY | -23.26% |
| 2007 | 9.91 Billion JPY | 1.64% |
| 2006 | 13.36 Billion JPY | -11.6% |
| 2005 | 8.54 Billion JPY | -1.86% |
| 2004 | 11.07 Billion JPY | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q3 | 1.79 Billion JPY | -1.43% |
| 2024 Q2 | 1.85 Billion JPY | 56.55% |
| 2024 Q1 | 1.49 Billion JPY | -49.15% |
| 2023 Q3 | 1.78 Billion JPY | -8.9% |
| 2023 FY | - JPY | -12.92% |
| 2023 Q4 | 1.94 Billion JPY | 9.26% |
| 2023 Q2 | 1.95 Billion JPY | 607.79% |
| 2023 Q1 | -385 Million JPY | -123.56% |
| 2022 Q3 | 1.46 Billion JPY | 18.45% |
| 2022 Q2 | 1.23 Billion JPY | -2.29% |
| 2022 FY | - JPY | 13.82% |
| 2022 Q1 | 1.26 Billion JPY | -21.18% |
| 2022 Q4 | 1.63 Billion JPY | 11.61% |
| 2021 FY | - JPY | -4.92% |
| 2021 Q4 | 1.6 Billion JPY | 12.95% |
| 2021 Q1 | 671 Million JPY | -46.7% |
| 2021 Q2 | 1.2 Billion JPY | 80.03% |
| 2021 Q3 | 1.42 Billion JPY | 17.63% |
| 2020 Q4 | 1.25 Billion JPY | 48.12% |
| 2020 Q1 | 1.31 Billion JPY | 54.64% |
| 2020 Q2 | 1.58 Billion JPY | 20.52% |
| 2020 Q3 | 850 Million JPY | -46.41% |
| 2020 FY | - JPY | 109.01% |
| 2019 Q3 | 435 Million JPY | -59.04% |
| 2019 Q4 | 851 Million JPY | 95.63% |
| 2019 FY | - JPY | -56.26% |
| 2019 Q1 | -657 Million JPY | -133.76% |
| 2019 Q2 | 1.06 Billion JPY | 261.64% |
| 2018 Q3 | 972 Million JPY | -29.1% |
| 2018 FY | - JPY | -19.26% |
| 2018 Q1 | 789 Million JPY | -70.44% |
| 2018 Q4 | 1.94 Billion JPY | 100.21% |
| 2018 Q2 | 1.37 Billion JPY | 73.76% |
| 2017 Q2 | 1.85 Billion JPY | 234.59% |
| 2017 FY | - JPY | 41.94% |
| 2017 Q4 | 2.66 Billion JPY | 101.89% |
| 2017 Q3 | 1.32 Billion JPY | -28.81% |
| 2017 Q1 | 555 Million JPY | -56.84% |
| 2016 Q2 | 1.06 Billion JPY | -12.76% |
| 2016 Q1 | 1.22 Billion JPY | -16.75% |
| 2016 FY | - JPY | -19.01% |
| 2016 Q4 | 1.28 Billion JPY | 204.02% |
| 2016 Q3 | 423 Million JPY | -60.36% |
| 2015 FY | - JPY | 30.1% |
| 2015 Q4 | 1.46 Billion JPY | 30.69% |
| 2015 Q3 | 1.12 Billion JPY | -35.7% |
| 2015 Q2 | 1.74 Billion JPY | 120.43% |
| 2015 Q1 | 793 Million JPY | 0.0% |
| 2014 Q3 | 1.66 Billion JPY | 131.15% |
| 2014 Q1 | 1.02 Billion JPY | -27.49% |
| 2014 FY | - JPY | -18.46% |
| 2014 Q2 | 719 Million JPY | -29.92% |
| 2013 Q4 | 1.41 Billion JPY | 7.6% |
| 2013 FY | - JPY | 54.86% |
| 2013 Q1 | -361 Million JPY | -133.61% |
| 2013 Q2 | 1.36 Billion JPY | 478.95% |
| 2013 Q3 | 1.31 Billion JPY | -3.87% |
| 2012 Q4 | 1.07 Billion JPY | 5.71% |
| 2012 FY | - JPY | -27.49% |
| 2012 Q1 | -6.26 Billion JPY | -8336.84% |
| 2012 Q2 | 1.22 Billion JPY | 119.52% |
| 2012 Q3 | 1.01 Billion JPY | -16.86% |
| 2011 FY | - JPY | -26.16% |
| 2011 Q2 | 3.5 Billion JPY | 170.39% |
| 2011 Q3 | 7.01 Billion JPY | 99.89% |
| 2011 Q4 | 76 Million JPY | -98.92% |
| 2011 Q1 | -4.98 Billion JPY | -215.98% |
| 2010 Q2 | 4.32 Billion JPY | 380.66% |
| 2010 FY | - JPY | -36.39% |
| 2010 Q4 | 4.29 Billion JPY | 11.58% |
| 2010 Q3 | 3.85 Billion JPY | -10.94% |
| 2010 Q1 | -1.54 Billion JPY | -132.29% |
| 2009 Q1 | -6.46 Billion JPY | -208.19% |
| 2009 Q2 | 4.28 Billion JPY | 166.26% |
| 2009 Q3 | 4.26 Billion JPY | -0.4% |
| 2009 Q4 | 4.77 Billion JPY | 11.94% |
| 2009 FY | - JPY | 12.99% |
| 2008 Q4 | 5.97 Billion JPY | 10.08% |
| 2008 Q3 | 5.42 Billion JPY | 0.0% |
| 2008 FY | - JPY | -23.26% |
| 2007 FY | - JPY | 1.64% |
| 2006 FY | - JPY | -11.6% |
| 2005 FY | - JPY | -1.86% |
| 2004 FY | - JPY | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Pharma Foods International Co., Ltd. | 6.02 Billion JPY | 12.456% |
| Takeda Pharmaceutical Company Limited | 874.6 Billion JPY | 99.397% |
| Sumitomo Pharma Co., Ltd. | -281.07 Billion JPY | 101.875% |
| Shionogi & Co., Ltd. | 186.7 Billion JPY | 97.177% |
| Wakamoto Pharmaceutical Co.,Ltd. | 570.97 Million JPY | -823.163% |
| Nippon Shinyaku Co., Ltd. | 36.29 Billion JPY | 85.475% |
| Kaken Pharmaceutical Co., Ltd. | 12.26 Billion JPY | 57.031% |
| Eisai Co., Ltd. | 103.1 Billion JPY | 94.888% |
| Morishita Jintan Co., Ltd. | 1.29 Billion JPY | -307.657% |
| Hisamitsu Pharmaceutical Co., Inc. | 18.34 Billion JPY | 71.26% |
| Mochida Pharmaceutical Co., Ltd. | 8.97 Billion JPY | 41.257% |
| Fuso Pharmaceutical Industries,Ltd. | 3.67 Billion JPY | -43.624% |
| Nippon Chemiphar Co., Ltd. | 1.4 Billion JPY | -275.695% |
| Tsumura & Co. | 30.77 Billion JPY | 82.871% |
| Kissei Pharmaceutical Co., Ltd. | 18.72 Billion JPY | 71.843% |
| Towa Pharmaceutical Co., Ltd. | 35.53 Billion JPY | 85.167% |
| Fuji Pharma Co., Ltd. | 6.88 Billion JPY | 23.409% |
| Zeria Pharmaceutical Co., Ltd. | 17.52 Billion JPY | 69.917% |
| KYORIN Holdings, Inc. | 10.29 Billion JPY | 48.805% |
| Taiko Pharmaceutical Co.,Ltd. | -3.75 Billion JPY | 240.56% |
| Daito Pharmaceutical Co.,Ltd. | 7.55 Billion JPY | 30.213% |
| SymBio Pharmaceuticals Limited | -714 Million JPY | 838.235% |
| MedRx Co., Ltd | -884.51 Million JPY | 695.919% |
| Mizuho Medy Co.,Ltd. | 5.53 Billion JPY | 4.792% |
| Solasia Pharma K.K. | -635 Million JPY | 930.079% |
| Modalis Therapeutics Corporation | -2.37 Billion JPY | 322.038% |
| ASKA Pharmaceutical Holdings Co.,Ltd. | 9.16 Billion JPY | 42.475% |
| Sawai Group Holdings Co., Ltd. | 36.87 Billion JPY | 85.705% |
| Cyfuse Biomedical K.K. | -538.28 Million JPY | 1079.214% |
| Toho Holdings Co., Ltd. | 25.84 Billion JPY | 79.605% |
| Koa Shoji Holdings Co.,Ltd. | 5.1 Billion JPY | -3.32% |